Moxonidin Al (Moxonidine)

Moxonidine, the active ingredient in Moxonidin Al, is an imidazoline receptor agonist presented as a tablet for oral use. It is employed to lower elevated blood pressure in adults with essential hypertension and is approved for clinical management of this condition in the European Union.

GNH USA supplies Moxonidin Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets. We adhere to stringent storage and handling standards to maintain product integrity.

Moxonidine acts on central imidazoline I1 receptors to control blood pressure in hypertension.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.

Moxonidine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially when standing quickly. - Headache: mild to moderate pain in the head. - Nausea: upset stomach, sometimes with mild vomiting. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Bradycardia: unusually slow heart rate requiring medical attention. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Electrolyte imbalance: rare disturbances in potassium or sodium levels.

Before initiating therapy, consider the following safety measures.

- Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use with caution; monitor liver enzymes. - Pregnancy: safety category unknown; avoid unless benefit outweighs risk. - Elderly patients: start at low dose and monitor for hypotension. - Concomitant antihypertensives: risk of additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Combined use with other central antihypertensives (e.g., clonidine) may cause profound hypotension. - Co‑administration with potent CYP2D6 inhibitors (if metabolized) could increase plasma levels.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia and require heart‑rate monitoring. - Diuretics: additive effect on blood pressure; monitor electrolytes. - Alcohol: can increase dizziness and hypotensive response.